Smallpox Vaccine Oncolytic Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are inadequate in effectively addressing solid tumors and hematologic malignancies, with cancer remaining a leading cause of death despite advances in anticancer therapies over the past 30 years.
Innovation Solution
Administration of a smallpox vaccine, either alone or in combination with stem cells, immune cells, or adipose-derived stromal vascular fraction, to activate the body's immune system and target cancer cells, using attenuated strains of the vaccinia virus for intratumoral or systemic delivery to induce immunogenic cell death.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments are used, then cancer remains a leading cause of death, but the treatments are inadequate in effectively addressing solid tumors and hematologic malignancies
Solution Approach 1:
The patent utilizes the smallpox vaccine (vaccinia virus), traditionally used for preventing smallpox, and repurposes it as an oncolytic agent to treat cancer. The virus that was harmful to smallpox victims is now converted into a beneficial treatment for cancer patients, demonstrating the principle of converting harm into benefit.
Solution Approach 2:
The smallpox vaccine is employed for multiple functions: it acts as both an immunostimulant to activate the immune system and as an oncolytic agent to directly kill cancer cells. This multi-functionality allows a single treatment to address multiple aspects of cancer therapy simultaneously.
2Reliability
If a smallpox vaccine is administered to treat cancer, then tumor size is reduced and immune response is induced, but the treatment involves using a replication competent virus which may pose safety concerns
Solution Approach 1:
The patent employs different strains of the vaccinia virus with varying degrees of attenuation (e.g., NYCBOH strain, MVA strain). By changing the parameter of viral attenuation, the treatment can be optimized to balance between oncolytic efficacy and safety, allowing the virus to kill cancer cells while minimizing potential harmful effects on healthy tissues.
Solution Approach 2:
The smallpox vaccine acts as an intermediary that triggers the patient's own immune system to fight cancer cells. Rather than directly attacking all cancer cells, the virus mediates the immune response by stimulating cytokine release and activating immune cells, which then target and destroy tumor cells more precisely.
3Reliability
If stem cells or immune cells are combined with the smallpox vaccine, then the immune response is enhanced and tumor eradication is improved, but the treatment complexity increases
Solution Approach 1:
The patent combines the smallpox vaccine with stem cells or immune cells in a single administration protocol. This merging of multiple therapeutic agents into one treatment approach enhances the immune response and tumor eradication efficacy while streamlining the treatment process compared to sequential therapies.
Solution Approach 2:
The treatment creates a composite therapeutic composition containing the vaccinia virus along with stem cells or immune cells. This composite approach leverages the synergistic effects of different cell types and the viral oncolytic activity, creating a more potent and comprehensive cancer treatment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach demonstrates significant safety and efficacy in reducing tumor size and achieving complete tumor eradication in some patients, with minimal side effects, while inducing a robust immune response and cytokine release, highlighting its potential as a novel cancer treatment strategy.
Implementation Method 1
administering to the subject a smallpox vaccine, which induces an immune response in the subject and kills the cancer cells
Implementation Method 2
the smallpox vaccine is a replication competent virus
Implementation Method 3
inducing an immune response in the subject and kills the cancer cells
Implementation Method 4
inducing a robust immune response and cytokine release
Data Source
AI summary
Disclosed herein are methods and compositions related to therapy for cancer. More specifically, the disclosed methods and compositions are related to the use of smallpox vaccine to induce an effective anti-tumor immune response.